Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes

BACKGROUND: The persistence of depressive symptoms after hospitalization is a strong risk factor for mortality after acute coronary syndromes (ACS). Poor adherence to secondary prevention behaviors may be a mediator of the relationship between depression and increased mortality. OBJECTIVE: To determine whether rates of adherence to risk reducing behaviors were affected by depressive status during hospitalization and 3 months later. DESIGN: Prospective observational cohort study. SETTING: Three university hospitals. PARTICIPANTS: Five hundred and sixty patients were enrolled within 7 days after ACS. Of these, 492 (88%) patients completed 3-month follow-up. MEASUREMENTS: We used the Beck Depression Inventory (BDI) to assess depressive symptoms in the hospital and 3 months after discharge. We assessed adherence to 5 risk-reducing behaviors by patient self-report at 3 months. We used chi2 analysis to compare differences in adherence among 3 groups: persistently nondepressed (BDI < 10 at hospitalization and 3 months); remittent depressed (BDI > or = 10 at hospitalization; < 10 at 3 months); and persistently depressed patients (BDI > or = 10 at hospitalization and 3 months). RESULTS: Compared with persistently nondepressed, persistently depressed patients reported lower rates of adherence to quitting smoking (adjusted odds ratio [OR] 0.23, 95% confidence interval [95% CI] 0.05 to 0.97), taking medications (adjusted OR 0.50, 95% CI 0.27 to 0.95), exercising (adjusted OR 0.57, 95% CI 0.34 to 0.95), and attending cardiac rehabilitation (adjusted OR 0.5, 95% CI 0.27 to 0.91). There were no significant differences between remittent depressed and persistently nondepressed patients. CONCLUSIONS: Persistently depressed patients were less likely to adhere to behaviors that reduce the risk of recurrent ACS. Differences in adherence to these behaviors may explain in part why depression predicts mortality after ACS.     

A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence

HIV-related stigma has a damaging effect on health outcomes among people living with HIV (PLWH), as studies have associated it with poor HIV medication adherence and depressive symptoms. We investigated whether depressive symptoms mediate the relationship between stigma and medication adherence. In a cross-sectional study, 720 PLWH completed instruments measuring HIV-related stigma, depressive symptoms, and HIV medication adherence. We used structural equation modeling (SEM) to investigate associations among these constructs. In independent models, we found that poorer adherence was associated with higher levels of stigma and depressive symptoms. In the simultaneous model that included both stigma and depressive symptoms, depression had a direct effect on adherence, but the effect of stigma on adherence was not statistically significant. This pattern suggested that depressive symptoms at least partially mediated the association between HIV-related stigma and HIV medication adherence. These findings suggest that interconnections between several factors have important consequences for adherence.     

Compliance with an oral asthma medication: a pilot study using an electronic monitoring device

Compliance with prescribed asthma medication is commonly estimated from tablet counts for oral medications and canister weights for inhaled medications. Recently, electronic medication monitoring devices, developed to evaluate numerical compliance as well as drug use patterns, were used to assess compliance with inhaled steroids and beta2-agonists. This was the first study to electronically assess compliance with an oral asthma medication. Fifty-seven asthmatic patients, stable on inhaled beta2-agonists only with a mean FEV1 of 77% predicted (+/- 13%, SD) began 12 weeks of treatment with zafirlukast 20 mg twice daily. The monitoring device, an electronic TrackCap, recorded the date and time on each occasion that patients removed and replaced their medication bottle caps. Patients were told that compliance would be assessed as part of the study, but patients were not told about the specifics of the TrackCap. Compliance was defined: 1. as the number of TrackCap events per number of prescribed tablets; and 2. as the difference between number of tablets dispensed and number returned per number prescribed. Adherence was defined as the number of days with two TrackCap events at least 8 h apart per the total number of days' dosing. Forty-seven patients completed the study with a median compliance of 89% (mean. 80%) and a median adherence of 71% (mean, 64%) as measured by TrackCap events. Compliance as estimated from return-tablet count was slightly higher (median, 92%). High rates of compliance were maintained throughout the trial. These results show that compliance with and adherence to a treatment of an oral, twice-daily, maintenance asthma medication, such as zafirlukast, is high.     

Pilot study examining the efficacy of an electronic intervention to promote HIV medication adherence

Widespread dissemination of current interventions designed to improve HIV medication adherence is limited by several barriers, including additional time and expense burdens on the health care systems. Electronic interventions could aid in dissemination of interventions in the clinic setting. This study developed and tested the feasibility and acceptability of a computer-based adaption of an empirically supported face-to-face adherence promotion intervention. HIV-positive individuals (N = 92) on antiretroviral therapy with self-reported adherence <95% were randomized to the electronic intervention + treatment as usual (TAU) or TAU only. Study outcome variables which included treatment self-efficacy and self-reported medication adherence were assessed at baseline and follow-up. Time × condition interaction effects in mixed model analysis of variance (ANOVAs) examined the differences in patterns of change in the outcome variables over time between the two groups. Participants in the electronic intervention condition reported higher levels of self-efficacy to adhere to their medication at follow-up compared to the control condition. Although nonsignificant, levels of adherence tended to improve over time in the intervention condition, while TAU adherence remained constant. This was the first study to investigate a single-session, computer-based adherence intervention. Results suggest that electronic interventions are feasible and this method may be effective at increasing self-efficacy and adherence among patients reporting suboptimal adherence levels.     

Long-term subcutaneous and oral anticoagulants after acute coronary syndromes.

Antithrombotic treatment of acute coronary syndrome consists of aspirin and (low-molecular weight) heparin, whereas oral glycoprotein IIb/IIIa receptor antagonists as a routine cannot be advised and thrombolytic therapy is not indicated at all. Long-term protection also consists of antiplatelet therapy and, if indicated, by anticoagulant therapy, given either as low-molecular weight heparin or as oral anticoagulants.     

Non-ST-segment elevation acute coronary syndromes: an algorithm for decision.

We have read with great interest the report¹ of the Task Forceconcerning the guidelines for the diagnosis and treatment ofnon-ST-segment elevation acute coronary syndromes (NST-ACS).We would like to compliment the Task Force members for thisexcellent work, updating the previous ESC guidelines concerningthat matter. In particular, the     

Influence of prior medication on mode of presentation and prognosis of acute coronary syndromes.

OBJECTIVES: To evaluate the influence of prior medication on mode of presentation and short-term prognosis of acute coronary syndromes (ACS). DESIGN: Prospective study. SETTING: Coronary intensive care unit in Santa Cruz Hospital. POPULATION: We included 425 consecutive patients admitted for ACS. METHODS: Prior medication with anti-platelet agents, beta-blockers, nitrates, calcium channel blockers, statins and angiotensin-converting enzyme (ACE) inhibitors was recorded on admission. Medication introduced in the last 7 days was excluded. Using a multivariate analysis model we examined the impact of baseline characteristics and previous medication on mode of presentation of ACS. We also evaluated their influence on short-term prognosis (death or non-fatal myocardial (re)infarction in the first 30 days). RESULTS: Of the 425 patients studied 228 (53.6%) presented with unstable angina (UA), the remainder with acute myocardial infarction (AMI) (24.7% with ST elevation). Medication prior to admission included anti-platelet agents in 53.7% of patients, beta-blockers in 44.2%, nitrates in 48.2%, calcium channel blockers in 36.9%, statins in 28.9% and ACE inhibitors in 38.6%. During the first 30 days, 14 deaths (3.3%) and 37 (re)infarctions (8.7%) occurred. The combined occurrence of death or (re)infarction was 10.8%. Variables with significant and independent influence on mode of presentation of ACS were male gender, presence of known coronary artery disease and previous medication with anti-platelet agents and beta-blockers. Male gender was a predictor of AMI as mode of presentation, whereas a previous history of coronary artery disease and medication with anti-platelet agents or beta-blockers predicted UA. Short-term prognosis was influenced by heart failure symptoms on admission, but not by previous medication. CONCLUSION: Previous medication with anti-platelet agents and beta-blockers was associated with an increased frequency of UA as mode of presentation of ACS. No relation between previous medication and short-term prognosis was observed in the present study.     

Predictors of antiretroviral adherence as measured by self-report,electronic monitoring,and medication diaries

This study reports on the prevalence and predictors of adherence as measured by self-report, medication diaries, and electronic monitoring. A sample of 180 patients receiving human immunodeficiency virus (HIV) antiretroviral therapy were randomized to one of three adherence surveillance methods (electronic monitoring caps, patient medication diaries, no surveillance control group) for 4 weeks, with adherence measured by self-report at study end point; 173 (96%) participants completed the study. Most participants were male (82%), non-white (68%), and unemployed (84%); mean self-reported CD4 count was 406 cells/mm,3 and 31% reported having undetectable viral load. The three methods of adherence measurement revealed moderate (electronic monitoring: 80.6%) to high (self-report: 93.7%; diaries: 92.6%) rates of adherence. Although there were differences across adherence measures, variables that were identified as correlates of lower adherence by all three methods included living with others or having a larger household, current symptomatology, and cognitive functioning deficits. This consensus across adherence measures strengthens the validity of these identified predictors and their potential value in informing the development of adherence interventions, as well as increases the validity of the three adherence measures.     

Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study

PURPOSE: To determine the rates of patient adherence to key evidence-based therapies at 6 months after hospital discharge for an acute coronary syndrome. METHODS: In this nonrandomized, prospective, multinational, multicenter study, adherence to aspirin, beta-blockers, statins, or angiotensin-converting enzyme (ACE) inhibitors 6 months after discharge for myocardial infarction or unstable angina was assessed in 21,408 patients aged 18 years or older. Patients were enrolled at 104 tertiary and community hospitals representing a broad range of care facilities and practice settings (e.g., teaching vs. nonteaching). RESULTS: Of 13,830 patients, discontinuation of therapy was observed at 6-month follow-up in 8% of those taking aspirin on discharge, 12% of those taking beta-blockers, 20% of those taking ACE inhibitors, and 13% of those taking statins. In a multivariate analysis, adherence to beta-blocker therapy was higher in patients with a myocardial infarction (odds ratio [OR] = 1.25; 95% confidence interval [CI]: 1.06 to 1.47), hypertension (OR = 1.33; 95% CI: 1.15 to 1.54), ST-segment elevation myocardial infarction (OR = 1.33; 95% CI: 1.11 to 1.61), or non-ST-segment elevation myocardial infarction (OR = 1.25; 95% CI: 1.08 to 1.45). Aspirin adherence was higher among patients cared for by cardiologists (OR = 1.45; 95% CI: 1.19 to 1.75; P <0.001) than among those cared for by nonspecialists. Male sex and prior heart failure were associated with improved adherence to ACE inhibitor therapy. Hypertension was associated with poorer adherence to statin therapy (OR = 0.85; 95% CI: 0.74 to 0.99; P = 0.04). CONCLUSION: Among patients prescribed key evidence-based medications at discharge, 8% to 20% were no longer taking their medication after 6 months. The reasons for noncompliance are complex, and may be elucidated by future studies of medical and social determinants.     

Typical symptoms are predictive of acute coronary syndromes in women

Background Previous research suggests that the presentation of acute coronary syndromes (ACS) may differ in women and men. No study has prospectively evaluated the role of a comprehensive set of typical and atypical symptoms and whether different symptoms on presentation predict ACS diagnosis in women and men. Methods and Results We directly observed 246 women and 276 men seen in the emergency department with symptoms suggestive of ACS and documented their symptoms verbatim. ACS was eventually diagnosed in 89 (36%) women and 124 (45%) men on the basis of standard electrocardiogram and cardiac enzyme criteria. Presence of typical symptoms (chest pain or discomfort, dyspnea, diaphoresis, and arm or shoulder pain) was significantly associated with a diagnosis of ACS in women but not in men. On the other hand, atypical symptoms were not related to ACS diagnosis in women, whereas in men some atypical symptoms (dizziness or faintness) were inversely associated with ACS (P = .007). In multivariate analysis, the only symptoms that showed significant or borderline associations with ACS in women were diaphoresis (P = .019) and chest pain or discomfort (P = .069). Chest pain or discomfort and other typical symptoms were not significantly associated with ACS in men. Adjusted relative risks for ACS associated with the presence of typical symptoms in women compared with men were close to 1.0, indicating no sex differences. Conclusions Typical symptoms are the strongest symptom predictors of ACS in women, and they are as important in women as in men. Clinicians need to take very seriously any woman who has typical symptoms and pursue a full cardiac work-up. (Am Heart J 2002;143:283-8.)     

症状对不同性别急性冠状动脉综合征的预测价值

目的 :前瞻性研究症状对不同性别急性冠状动脉综合征 (ACS)的诊断是否有预测价值。方法 :2 0 0 0年 1月 1日～ 2 0 0 3年 3月 31日 ,我们对连续拟诊ACS行急诊冠状动脉介入的 74 0例患者进行了观察 ,男 5 2 8例 ,女 2 12例 ,对比分析男女患者的预测症状。结果 :根据心电图、心脏标志物和冠状动脉造影 ,最后诊断为ACS女性 184例 ( 86 .8% ) ,男性 4 80例 ( 90 .9% )。女性有典型症状 (胸痛或不适、呼吸困难、出汗、臂或肩痛 )者诊断为ACS明显多 ,男性则不 ;相反 ,女性有不典型症状者诊断ACS不多 ,而在男性 ,一些不典型症状 (头晕或头昏 )与ACS的诊断呈反相关系 (P <0 .0 5 )。多因素分析表明 ,出汗 (P <0 .0 5 )和胸痛 (P >0 .0 5 )与女性ACS的诊断呈显著或边缘相关 ;而胸痛等典型症状与男性ACS无明显相关 ( P >0 .0 5 )。与男性相比 ,有典型症状的女性诊断ACS的调整相对危险性接近 1.0 ,提示无性别差异。结论 :典型症状是诊断女性ACS的最强症状预测因素 ,与男性一样重要     

Pillboxes and antiretroviral adherence: prevalence of use, perceived benefits, and implications for electronic medication monitoring devices

HIV treatment adherence is improved by behavioral interventions, including medication organizers such as pillboxes, which can also interfere with adherence electronic monitoring devices (EMD). This study examined the characteristics of pillbox users and the implications of pillbox use for research using EMD adherence research. Men and women (n = 160) currently taking antiretroviral medications (ARVs) completed anonymous surveys in a community research setting. Sixty-three (39%) of individuals taking ARVs were currently using a pillbox. Pillbox users were significantly more likely to have an undetectable viral load and less likely to have missed their medications within a day of the assessment. Pillbox users indicated feeling that they benefited from using their pillbox and 76% reported they would likely stop using their pillbox if required to participate in a research study that paid them. Adherence EMD pose methodological limitations to research when pillbox users are excluded and ethical implications when pillbox users stop using their pillbox to participate.